Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22319775 | 0.79 | MAPT (0.40) | KDM4EMAPTLMNASMN1; SMN2 | |
| SCHEMBL23261786 | 0.72 | PARP15 (0.37) | KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL23261787 | 0.72 | MAPT (0.33) | KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL20276015 | 0.72 | GPR55 (0.30) | GPR55 | |
| SCHEMBL8737227 | 0.71 | GPR55 (0.32) | GPR55TRPA1LMNACHRM1SLC6A2 | |
| SCHEMBL10938436 | 0.65 | LMNA (0.39) | GPR55TRPA1LMNACHRM1SLC6A2 | |
| SCHEMBL12053508 | 0.64 | KDM4E (0.41) | KDM4EMAPTGPR55LMNASMN1; SMN2 | |
| SCHEMBL6124134 | 0.64 | TRPA1 (0.32) | TRPA1LMNACHRM1SLC6A2ADRA1A | |
| SCHEMBL8737563 | 0.63 | GPR55 (0.39) | GPR55TRPA1LMNACHRM1SLC6A2 | |
| SCHEMBL6127878 | 0.63 | GPR55 (0.32) | GPR55TRPA1LMNACHRM1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239813-A1 | KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239813-A1 | KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF | KRAS, NRAS, HRAS | KDM4E 4061/4885MAPT 3259/4885GPR55 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.